Price
Target price
€72.50
€72.50
2.840%
-
2.840%
€70.96
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
There is an upward development for Protagonist Therapeutics Inc compared to yesterday, with an increase of €0.000 (2.840%).
With 28 Buy predictions and 1 Sell predictions Protagonist Therapeutics Inc is one of the favorites of our community.
However, we have a potential of -3.45% for Protagonist Therapeutics Inc as the target price of 70 € is below the current price of 72.5 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Recent market speculation linking Johnson & Johnson (NYSE: JNJ) to a complete acquisition of its partner, Protagonist Therapeutics (NASDAQ: PTGX), offers a valuable glimpse into a core corporate
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
Clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense